Subpopulation Heterogeneity of NK Cells during the Genetic Modification for Subsequent Use in Targeted Therapy

M A Streltsova; A A Boyko; M O Ustiuzhanina; A I Palamarchuk; N A Alekseeva; R A Velichinskii; J D Vavilova; M V Grechikhina; A M Sapozhnikov; S M Deev; E I Kovalenko

doi:10.1134/S1607672922340142

Subpopulation Heterogeneity of NK Cells during the Genetic Modification for Subsequent Use in Targeted Therapy

Dokl Biochem Biophys. 2022 Dec;507(1):380-382. doi: 10.1134/S1607672922340142. Epub 2023 Feb 14.

Authors

M A Streltsova¹, A A Boyko¹, M O Ustiuzhanina^{1

2}, A I Palamarchuk¹, N A Alekseeva¹, R A Velichinskii¹, J D Vavilova¹, M V Grechikhina¹, A M Sapozhnikov¹, S M Deev^{1

3}, E I Kovalenko⁴

Affiliations

¹ Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia.
² Skolkovo Institute of Science and Technology, Moscow, Russia.
³ Sechenov First Moscow State Medical University, Ministry of Healthcare of the Russian Federation, 119992, Moscow, Russia.
⁴ Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia. [email protected].

PMID: 36787007
DOI: 10.1134/S1607672922340142

Abstract

Obtaining genetically engineered NK cells is a developing area of immunotherapy. In this work, we analyzed the subset heterogeneity of NK cells subjected to retroviral transduction, taking into account the content of adaptive NK cell progenitors. It was shown that subsets KIR2DL2/DL3⁺, as well as CD57^-KIR2DL2/DL3⁺NKG2C⁺, can be modified with greater efficiency than the corresponding subsets that do not carry the KIR2DL2/DL3 and NKG2C markers. After genetic modification, the CD57^-KIR2DL2/DL3⁺NKG2C⁺ cells began to express CD57 de novo, acquiring the adaptive NK cell phenotype.

Keywords: NK cells; adaptive NK cells; immunotherapy; modification; proliferative potential; sensitivity to modification; transduction.

MeSH terms

Cytomegalovirus Infections*
Cytomegalovirus*
Humans
Killer Cells, Natural
Phenotype